A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer

Advanced Pancreatic Carcinoma Clinical Trial

Official title:

A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05257122
• Other study ID #: FDZL-FPcT
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: February 2022
• Est. completion date: February 2024

Study information

• Verified date: February 2022
• Source: Fudan University
• Contact: Jieyun Zhang
• Phone: +8618801735823
• Email: Dr_JYZ[@]outlook.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy

Description:

This study is an open Label, non-randomized, single-arm and multi-centered phase II clinical trial. It plans to evaluate the safety and efficacy of fruquintinib in advanced pancreatic cancer patients who failed second-line gemcitabine or 5-FU based chemotherapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 32
• Est. completion date: February 2024
• Est. primary completion date: September 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. 18-80 years old;

2. Locally advanced or recurrent/metastatic pancreatic adenocarcinoma confirmed by cytological or histopathological examination;

3. Have failed second-line chemotherapy (gemcitabine or 5-FU-based regiments) (the definition of treatment failure is: toxic and side effects are intolerable, disease progression during treatment, recurrence within six months after the end of adjuvant chemotherapy, or progression within three months after the end of palliative chemotherapy); prior chemotherapy are required to include gemcitabine or 5-FU or its derivatives;

4. With one or more measurable lesions, the longest diameter should be at least 10 mm measured by spiral CT scan, or at least 20 mm by conventional CT scan should be(RECIST standard, version 1.1);

5. ECOG score was 0-2;

6. Life expectancy =12 weeks;

7. The damage was recovered from other antitumor treatments, including the interval from nitroso or mitomycin to enrollment was =6 weeks, and the interval from other cytotoxic drugs, radiotherapy or surgery to enrollment was =4 weeks, and the wound was completely healed;

8. Acceptable hematologic, hepatic, and renal function within 7 days from screenin:

absolute neutrophil count (ANC) =1.5x109 /L; Hemoglobin = 9.0g/dL; Platelet count =80 x109 /L; Total bilirubin < 1.5 times upper limit of normal (ULN); ALT and AST< 2.5 x ULN (with liver metastasis <5x ULN); Serum creatinine =1 x ULN, endogenous creatinine clearance rate >50ml/min;

9. Women of reproductive age need to take effective contraceptive measures;

10. Participate in this study is voluntarily and sign informed consent. With good compliance to cooperate with the follow-up, participate should understand the purpose of this study and the necessary procedures.

Exclusion Criteria:

1. A history of other malignant tumors in the past 5 year: however, localized tumor cured in the study is excluded, including cervical carcinoma in situ and skin basal cell carcinoma.

2. Patients with hypertension that could not be controlled by antihypertensive drug therapy (systolic blood pressure >140mmHg, diastolic blood pressure >90mmHg), coronary heart disease of grade 1 or above, arrhythmia of grade 1 or above (including prolonged QTc interval > 450ms in males and > 470ms in females) and cardiac dysfunction of grade 1 or above;

3. Symptomatic brain or meningeal metastases (except those with stable brain metastases for more than one month after treatment);

4. Have a history of uncontrolled epileptic seizures, central nervous system dysfunction, or mental disorders;

5. Uncontrolled pleural or abdominal effusion;

6. Undergoing kidney dialysis;

7. Severe or uncontrolled infection;

8. With multiple factors affecting oral medication (inability to swallow, chronic diarrhea and intestinal obstruction);

9. Abnormal coagulation function (PT>16s, APTT>43s, TT>21s, Fbg< 2g/L), bleeding tendency, receiving thrombolytic or anticoagulant treatment, and a history of thrombosis or embolism within six months;

10. Patients at risk of gastrointestinal bleeding should not be enrolled, including: (1) patients with active digestive ulcer lesions and fecal occult blood (2+ or above); (2) patients with history of black stools and hematemesis within 3 months; (3) Patients with gastrointestinal fistula or perforation.

11. Participated in other medicine clinical trials within four weeks.

12. Weight less than 40kg.

13. Urine protein =2+ by urine routine

Related Conditions & MeSH terms

• Advanced Pancreatic Carcinoma
• Pancreatic Neoplasms

Intervention

Drug:
• Fruquintinib
Fruquintinib 5mg qd, d1-21, q28d

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Fudan University	Zhejiang Provincial People's Hospital

Country where clinical trial is conducted

China, 

References & Publications (4)

Cao J, Zhang J, Peng W, Chen Z, Fan S, Su W, Li K, Li J. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with adv — View Citation

Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Fan S, Hua Y, Su W. Effect of Fruquintinib — View Citation

Martin LK, Li X, Kleiber B, Ellison EC, Bloomston M, Zalupski M, Bekaii-Saab TS. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluoroura — View Citation

Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L, Philip PA. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression free survival (PFS)	The time from confirmation of enrollment to tumor progression or death from any cause, whichever came first	up to 24 months
Secondary	overall survival (OS)	The time from randomization to death from any cause, whichever came first	up to 36 months
Secondary	objective response rate (ORR)	The proportion of patients whose tumors shrink to a certain extent and remain constant for a certain period of time	through study completion, an average of 2 year
Secondary	disease control rate (DCR)	percentage of cases with response to treatment (PR+CR) and disease stability (SD) that can be evaluated	through study completion, an average of 2 year
Secondary	duration of response (DoR)	the length of time that a tumor continues to respond to treatment without the cancer growing or spreading	through study completion, an average of 2 year
Secondary	safety: the potential side effects	the potential side effects	through study completion, an average of 2 year